"Darbepoetin alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.
| Descriptor ID |
D000068256
|
| MeSH Number(s) |
D12.776.395.240.150.500
|
| Concept/Terms |
Darbepoetin alfa- Darbepoetin alfa
- Novel Erythropoiesis Stimulating Protein
- NESP
- Darbepoietin alfa
|
Below are MeSH descriptors whose meaning is more general than "Darbepoetin alfa".
Below are MeSH descriptors whose meaning is more specific than "Darbepoetin alfa".
This graph shows the total number of publications written about "Darbepoetin alfa" by people in this website by year, and whether "Darbepoetin alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Darbepoetin alfa" by people in Profiles.
-
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
-
Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
-
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
-
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
-
De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2018 Jan; 33(1):125-137.
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.